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an identical antibody treatment protocol. Resolving that con-Antibodies to both ICAM-1 and LFA-1 do not protect the
troversy should bring better insight in fundamental processeskidney against toxic (HgCl2) injury.
underlying different types of ARF, and will be the subject ofBackground. The role of inflammatory leukocytes in acute
further study.renal failure (ARF) remains controversial and appears largely
uninvestigated in toxic (in contrast to ischemic) ARF.
Methods. Female Wistar rats were injected with monoclonal
antibodies (mAbs) directed to both the leukocyte function-
Despite its high vulnerability for the exposure to toxicassociated antigen 1 (LFA-1) and the intercellular adhesion
agents or to an episode of oxidative stress, the kidneymolecule 1 (ICAM-1). Doses (6 mg/kg of each mAb) were
given 24 hours prior to the induction of acute tubular necrosis demonstrates an impressive regeneration capacity [1–4].
(ATN) by mercuric chloride administration (2 mg/kg, subcuta- A protective/regenerative or in contrast detrimental or
neously, day 0) and subsequently every 48 hours. Control rats mere clean-up potential has been proposed for the numer-similarly received either control antibody (12 mg/kg) or vehicle
ous inflammatory leukocytes always present in the kid-prior to and following the induction of ATN. Renal function
ney during the process of injury and/or subsequent regen-was also measured from male Lewis rats that were similarly
treated with anti-adhesion antibodies during exposure to 30 eration [5–10]. Macrophages and also both subsets of T
minutes of unilateral renal ischemia. lymphocytes remain localized predominantly in the zone
Results. Injected antibodies were demonstrated on periph- of most severe injury for as long as the process of restor-eral blood leukocytes (flow cytometrical detection of mouse
ing renal tubular morphology and function lasts [11, 12].anti–LFA-1) and on endothelium (immunohistochemical stain-
Polymorphonuclear cells, but also macrophages, indeeding of mouse anti–ICAM-1) and were measured in serum (en-
zyme-linked immunosorbent assay). Macrophages and T cells can release damaging agents such as oxygen radicals and
were prominent in the kidney of control treatment rats after nitric oxide [13]. Moreover, a leukocyte infiltrate is well
HgCl2 injection, but anti-adhesion treatment clearly had pre- equipped to produce and secrete vasoactive substancesvented their infiltration. Notwithstanding, renal tubular injury
that, in turn, may functionally influence the kidney [14].was equally pronounced in all mercuric chloride treatment groups
and so was the decline in renal function (serum creatinine, pro- Activated mononuclear cells, on the other hand, can
teinuria). Tubular epithelial cell proliferation seemed slightly produce variable kinds of growth factors able to promote
less pronounced and delayed in anti-adhesion treated rats. Kid- epithelialization, angiogenesis, and/or extracellular ma-neys from ischemia exposed rats were, however, functionally
trix turnover [15, 16].protected by identical anti–ICAM-1/anti–LFA-1 treatment.
Different molecular partners of leukocytes and endo-Conclusion. Prevention of cellular infiltration by mAbs to
LFA-1 and ICAM-1 has no effect on renal morphology, func- thelial cells involved in adhesion, a crucial step toward
tion, or regeneration following mercuric chloride-induced ARF inflammation, are becoming more readily known, and
in the rat. This result contrasts with the functional protection
preventing the interaction between them may indeed keepof the rat kidney to ischemia/reperfusion injury by virtue of
leukocytes from proceeding to endothelial diapedesis
[17, 18]. Of the leukocyte integrins that appear most com-
monly in leukocyte-endothelial adhesion, only CD11a/1 Present address: Laboratory of Neurobiology and Neuroendocrinoim-
munology, University of Antwerp, Belgium. CD18 [leukocyte function-associated antigen 1 (LFA-1)]
is constitutively expressed by all leukocytes [19–24]. ItsKey words: acute renal failure, adhesion molecules, mercuric chloride,
nephrotoxicity. major ligand, the Ig-like intercellular adhesion molecule 1
(ICAM-1) [25, 26], is constitutively expressed at low
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molecules have been implicated in ischemia/reperfusion were subsequently conjugated either with fluoresceine
isothyocyanate (FITC) [44] or with biotin (b) [45], ac-(I/R) injury of the kidney [27] as well as the heart [28]
and the liver [29, 30]: these organs became successfully cording to a standard protocol.
protected by a variety of direct/indirect methods targeting
Experimental designICAM-1 (anti–ICAM-1 antibodies [27], ICAM-1 knock-
out mice [31], antisense oligonucleotides for ICAM-1 Female Wistar rats (180 to 200 g) were individually
housed in metabolic cages one day prior to the start of[32], etc.). Studies investigating the importance of adhe-
sion molecules in toxic ARF are limited to a very recent the experiment, and particular attention was given to the
cleanness of their cages and to their handling. Standardone involving cisplatin [33].
We investigated whether the combined treatment with rat chow and fresh tap water were supplied ad libitum,
and a 12-hour light/dark cycle was respected during themonoclonal antibodies (mAbs) directed to CD11a/CD18
(LFA-1) and its major ligand, ICAM-1, could influence entire experimental period. Rats were injected intraperi-
toneally with sterile solutions of: (1) mAb WT1 (mousethe infiltration behavior of different leukocyte subsets
in our previously optimized toxic model of mercuric chlo- IgG2a) directed against LFA-1 (6 mg/kg) and mAb 1A29
(mouse IgG1) reactive with ICAM-1 (6 mg/kg); (2) con-ride (HgCl2)-induced acute renal failure (ARF) in the
rat [34]. Disease progress and subsequent recovery after trol mAb (7E8, antihuman placental alkaline phospha-
tase or h-PLAP; mouse IgG1; 12 mg/kg); or (3) vehicleHgCl2 injection were compared at renal functional and
morphological level between rats treated with antibodies (PBS). Injections were performed 24 hours prior to (day 1)
induction of acute tubular necrosis (ATN; day 0) by ato adhesion molecules and those treated with a control
antibody or with vehicle. single administration of mercuric chloride (HgCl2, 2 mg/kg
subcutaneously) and were repeated every 48 hours. Se-
rum titers of antibody were measured throughout the
METHODS
experiment. During the subsequent 10-day observation
Production, purification, and quality assurance of mAbs period, four rats of each group were sacrificed at different
time intervals (days 1, 2, 4, 6, and 10). At each of theseExcept for the hybridoma producing mAb 7E8 (anti-
human placental alkaline phosphatase) [35], hybridoma time points, one additional rat exposed to treatments 1
through 3 that had, however, not been given mercuriccell lines producing mAbs (antirat mAbs: WT.1,LFA-1,
1A29,ICAM-1, OX-35,CD4) were obtained from the chloride was sacrificed and served as noninjured control.
All rats were weighed daily. Blood samples were ob-European Collection of Animal Cell Culture. mAbs
PC10,human proliferating cell nuclear antigen-PCNA tained by tail vein bleeding. Serum creatinine concentra-
tion was determined colorimetrically by Jaffe´’s method(Dako, Carpinteria, CA, USA), ED1,rat macrophages
(Serotec, Oxford, UK) and also OX-8 (Caltag, Bur- [46]. Protein concentration in 24-hour urine samples was
determined colorimetrically by Bradford’s method [47].lingame, CA, USA) were purchased [36–41]. Hybridoma
cells were grown in RPMI 1640 buffered by 25 mmol/L In an additional experiment, male Lewis rats (250 g)
were treated similarly with 6 mg/kg of both mAb WT1HEPES and supplemented with 300 mg/mL l-glutamine
(Life Technologies, Grand Island, NY, USA). The initial (anti–LFA-1) and mAb 1A29 (anti–ICAM-1) at the time
of exposure of one kidney to 30 minutes of ischemiagrowth medium supplement of 15% fetal calf serum
(FCS; Life Technologies) was lowered to 5% prior to (intravenous, day 0), and subsequently every 48 hours.
transfer of the cells from customary culture flasks to a
Flow cytometric analysis of peripheral blood leukocytesspecialized roller bottle (mini-PERM; Heraeus Instru-
ments, Ofterode am Harz, Germany) [42] in order to Leukocytes in 25 mL of heparinized peripheral blood
obtained from rats between subsequent antibody injec-increase the antibody production rate. Secreted antibod-
ies were purified from culture supernatant by affinity tions were double labeled to detect bound injected anti-
body and free LFA-1. After red blood cell lysis by thechromatography with protein A (Bioprocessing, Consett,
UK) and dialyzed against phosphate-buffered saline addition of 10 volumes of lysis buffer [163 mmol/L NH4Cl,
10.5 mmol/L KHCO3, 105 mmol/L ethylenediaminetetra-(PBS). Denaturing sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) in reducing con- acetic acid (EDTA); centrifugation during 7 minutes at
120 g; room temperature] and subsequent washing (PBS 1ditions confirmed the absence of contamination of anti-
body solutions with non-IgG proteins (.90% pure 0.1% bovine serum albumin 1 0.05% sodium azide; cen-
trifugation during 7 minutes at 120 g), leukocytes weremAb), and protein concentration was determined spec-
trophotometrically at 280 nm. Pure antibody solutions incubated with biotinylated rabbit-anti-mouse immuno-
globulins (RAM-b; Dako) that in our case would bindmeant for in vivo application were assured to contain
less than 20 endotoxin units [43] per mg protein (LAL to cells that had bound the injected antibodies. RAMb was
visualized by the addition of phycoerythrin-conjugatedcolorimetric test, end-point method; bio-Whittacker,
Walkersville, MD, USA). Some of the purified mAbs streptavidin (SA-PE; Becton Dickinson, Mountain View,
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CA, USA). Next, the remaining binding sites on RAM-b Histologic evaluation of renal tubular damage
for mouse IgG were blocked by normal mouse serum. Four micrometer sections from methacarn-fixed, par-
Finally, FITC-conjugated anti–LFA-1 (WT.1-FITC) was affin-embedded tissue were stained with periodic acid-
added to assure that LFA-1 molecules on leukocytes were Schiff (PAS) reagent and methyl green (nuclei). To eval-
saturated with injected anti–LFA-1 (WT.1). Incubations uate tubular epithelial cell injury, both in the renal cortex
were performed cold (48C) and in the dark, and were and outer stripe of outer medulla (OSOM) of each ani-
separated by washing steps. Labeled cells were kept in mal, 30 proximal and distal tubules were assigned a score
washing buffer (dark, 48C) until analysis. indicating intact tubules, tubules with damaged or ne-
Individual leukocytes were interrogated in a FACStar crotic cells, and completely necrotic tubules. Cells show-
PLUS flow-cytometer from Becton Dickinson (Immuno- ing excessive vacuolization, swelling, or membrane irreg-
cytometry Systems) using a 488 nm light beam originat- ularities were considered damaged. Cells showing a
ing from an Argon-ion laser set at 40 mW power. Data ruptured cell membrane or an extruded nucleus were
acquisition was assisted by the lysis II software package. considered necrotic. The tubules were scored at a magni-
The number of white blood cells was counted by an fication of at least 3320.
automated blood cell analyzer (Technicon H1; Bayer,
Immunohistochemical stainingsBrussels, Belgium).
Four micrometer sections from paraffin embedded tis-
Serum titers of injected mouse antibodies sue or 6 mm air-dried frozen sections were washed in
Serum titers of injected mouse IgG1 (1A29 5 anti-rat TSB (0.01 mol/L Tris-HCl, pH 7.6, in 0.9% NaCl) supple-
ICAM-1 or 7E8 5 anti-human PLAP) and IgG2a (WT1 5 mented with 0.1% Triton X-100 and 1% bovine serum
anti-rat LFA-1) were monitored by enzyme-linked im- albumin, respectively, and were subsequently exposed
munosorbent assay (ELISA) throughout the experi- to 2 3 5 minutes of microwave heating (0.01 mol/L Na
ment. For this purpose, immunoplates were coated with citrate). As evidenced by appropriate control experi-
a rabbit polyclonal antibody recognizing mouse immuno- ments, this treatment denatured injected mouse mAbs
globulins (RAM) from which cross-reactivity with rat IgG (anti–LFA-1 and anti–ICAM-1 or anti–h-PLAP) present
had been previously removed (Dako, Glostrup, Denmark). in the kidney that could otherwise also lead to staining.
Secondary biotinylated polyclonal antibodies raised in Then sections were blocked by normal horse serum (one
goat were directed to mouse IgG1 or to mouse IgG2a, fifth in TSB). Following overnight incubation with pri-
respectively (Pharmingen, San Diego, CA, USA). After mary mouse antibody (OX8, ED1, PC10, or 1A29), wash-
amplification by a complex of avidin and biotinylated ing in TSB, and rinsing in distilled water, endogenous
horse radish peroxidase, color was developed (OD405nm) peroxidase activity was suppressed in frozen sections by
by the addition of 2,29azino-di (3-ethyl benstialozine sul- a 15-minute incubation in methanol, rinsing in water,
fonate) (ABTS) [6] and hydrogen peroxide at pH 4.3 and a 30-minute incubation with 0.03% H2O2 in TSB.
(5.5 mg ABTS in 10 mL phosphate/citrate buffer and After additional washing (TSB), the sections were incu-
200 mL 1% H2O2). Mouse mAbs directed to the hapten bated for 30 minutes with biotinylated horse anti-mouse
trinitrophenol (TNP) of either the IgG1 or IgG2a isotype IgG and were washed (TSB), followed by a 60-minute
served as standards and were purchased from Phar- incubation with the avidin-biotin complex (Vectorstain;
mingen. Vector Laboratories, Burlingame, CA, USA). Washing
(3 3 TSB) preceded the preparation for color develop-
Animal sacrifice and renal tissue preparation ment. Then the peroxidase substrate solution [either 20 mg
Rats were sacrificed under ether anesthesia by cardiac 3-amino-ethyl-carbazole (Sigma, St. Louis, MO, USA)
puncture. Left kidneys were decapsulated, rinsed in 0.9% in 24 mL dimethyl sulfoxide, 200 mL acetate, pH 5 to
NaCl, and weighed. They were cut into approximately 5.2, and 4 mL 0.3% H2O2; or 0.5 mg/mL 3,39-diaminoben-
2 mm thick slices and were either immediately fixed in zidine (tetrahydrochloride; Sigma) in 0.1 mol/L Tris-HCl,
methacarn (60% methanol, 10% acetic acid, 30% trichlor- pH 7.6, with 0.03% H2O2] was added. The sections were
ethane, 4 h at room temperature) or formol-calcium fixa- lightly counterstained with hematoxylin and covered in
tive (4% formaldehyde—BDH—in 0.1 mol/L Na-caco- glycerin-gelatin or in DPX (BDH) mounting medium,
dylate, pH 7.4, with 1% CaCl2; 1.5 h at room temperature). respectively.
Formol calcium-fixed slices were rinsed in buffer without As the CD4 molecule could no longer be recognized by
formol and were subsequently frozen between gold- diverse mAbs (OX-35, OX-38, W3/25) after microwave
plated copper blocks at liquid nitrogen temperature. treatment, CD4-positive cells were immunohistochemi-
Methacarn-fixed tissue was rinsed in 70% ethanol and cally stained by means of a biotinylated anti-CD4 mAb
was dehydrated and embedded in low-melting point par- (OX-35-b). Reduction of signal amplification by omis-
sion of incubation with secondary anti-mouse polyclonalaffin (528C, BDH).
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antibody, however, makes this procedure much less sen- serum titers of mouse IgG1 (1A29 or 7E8) and IgG2a
(WT1) throughout the experiment.sitive. Immunohistochemical detection of injected anti–
ICAM-1 bound to endothelium was established on sec- Figure 1 shows a flow cytometric analysis of PBL la-
beled either with FITC-conjugated anti–LFA-1 (WT1-tions that had not been placed in the microwave but that
were pretreated with trypsin (5-min exposure to 0.003% FITC) alone prior to antibody injection at day 21 (Fig.
1A) or dual labeled with biotinylated rabbit-anti-mousetrypsin type III) instead and that were not incubated
with a primary mAb. immunoglobulins (RAM-b 1 SA-PE) and with FITC-
conjugated anti–LFA-1 mAb (WT1-FITC) after the first
Tubular epithelial cell proliferation and interstitial antibody injection at day 0 (Fig. 1 B–E), as explained in
leukocyte accumulation the Methods section. In control conditions (Fig. 1A), three
Immunohistochemical staining for PCNA on 4 mm sec- subsets of cells differentially expressing the LFA-1 anti-
tions of methacarn-fixed paraffin-embedded tissue com- gen can be distinguished. These weakly, intermediately,
bined with the PAS staining permitted counting of posi- or highly LFA-1–positive cells previously were shown to
tive cells with the distinction made between proximal and be lymphocytes, polymorphonuclear cells, and mono-
distal tubular cross-sections and the interstitium. The num- cytes, respectively [48]. After injection with control mAb
ber of positive cells in the OSOM (25 microscopic fields, 7E8 (Fig. 1 B, C), no positive cells could be detected by
magnification 3320, total surface 2.68 mm2) is expressed mere (in vitro) addition of rabbit-anti-mouse polyclonal
per square millimeter. Staining for macrophages (mAb antibody (RAM-b 1 SA-PE; Fig. 1B). Labeling with
ED1) was performed on 4 mm sections of methacarn- FITC conjugated WT.1 (anti–LFA-1; Fig. 1C), on the
fixed, paraffin-embedded tissue. In the OSOM (30 micro- other hand, resulted as expected in the distinction of
scopic fields, magnification 3320, total surface 3.22 mm2), three cell subsets similar to those seen in Figure 1A.
the number of ED1-positive cells per square millimeter In contrast, injection of the anti–ICAM-1/anti–LFA-1
was counted. CD8 (Ts/c and NK cells)-positive cells and antibody mixture (Fig. 1 D, E) resulted in three subsets
CD4-positive cells were stained on formol calcium-fixed, of PBL becoming detectable after in vitro addition of
frozen sections by mAbs OX-8 and W3/25, respectively, “RAM-b 1 SA-PE” (Fig. 1D), which is in accordance
and were quantitated according to the procedure de- with the normal expression of LFA-1 on rat PBL (Fig.
scribed for macrophages (45 microscopic fields, magnifi- 1A). These RAM-binding cells were nearly saturated
cation 3320, total surface 4.82 mm2). Hematoxylin and with injected anti-LFA-1 (WT.1) since hardly any of in
eosin staining was performed to estimate polymorphonu- vitro added FITC-conjugated WT.1 could bind (Fig. 1E).
clear neutrophil (PMN) presence. A comparison of renal tissue sections originating from
rats injected in vivo with anti–ICAM-1/anti–LFA-1 (Fig.
Statistical analysis 2A) or control mAb 7E8 (Fig. 2B) and sacrificed at day 4
Statistical analysis was performed with SYSTAT 7.0 immunohistochemically stained with horse-anti-mouse
for Windows, and significant differences are reported in polyclonal antibody shows intense staining of renal vas-
the Results section. Significant increases (P , 0.007) culature in the former (Fig. 2A), while the latter (Fig. 2B)
within one treatment group of serum creatinine and uri- sections were negative. This staining pattern in kidneys
nary protein excretion were demonstrated by paired t-tests from anti–ICAM-1/anti–LFA-1 treated rats corresponds
(days 21, 1, 2, 4, 6, 8, and 10 vs. day 0). Leukocyte infiltra- to immunohistochemical staining for ICAM-1 on renal
tion data and PCNA positivity obtained at different times tissue from non–antibody-treated HgCl2 ARF rats at day
of sacrifice (days 1, 2, 4, 6, and 10) within each group were 4 (Fig. 2C) and thus presumably represents ICAM-1
compared with untreated non-HgCl2–injected animals by expressing endothelial cells to which injected mouse-
Mann–Whitney U-tests. Furthermore, at each time point, antirat ICAM-1 (mAb 1A29) is bound.
it was tested by Mann–Whitney U-test whether anti– The administration protocol appeared sufficient to
ICAM-1/anti–LFA-1 treated groups differed from either provide a constant excess of circulating mAbs so that
control mAb or vehicle-treated groups. Significance lev- both ICAM-1 and LFA-1 could be maximally blocked
els (P , 0.05) needed not to be adjusted since multiple by 1A29 (IgG1) and WT1 (IgG2a), respectively. Serum
comparisons with the same data set were not performed. titers of injected mAbs (specific as well as control) in-
creased with first (day 21) and second (day 0) injections,
after which subsequent injections maintained a plateau.RESULTS
Concentrations of control antibody (12 mg/kg/injection)
Efficacy of antibody treatment remained somewhat higher than this of anti-ICAM-1 1
Antibody targeting. Successful antibody injection was anti-LFA-1 [(6 mg/kg 1 6 mg/kg)/injection], since the
demonstrated by: (1) flow-cytometric demonstration of former does not bind to rat antigens (data not shown).
anti–LFA-1 bound to peripheral blood leukocytes (PBLs); Interstitial leukocyte infiltration. In both control groups
(2) immunohistochemical detection of anti–ICAM-1 (control antibody 5 7E8; vehicle 5 PBS), renal intersti-
tial macrophages (ED1 stained) reached numbers as highbound to endothelium; and (3) monitoring (ELISA) of
Ghielli et al: Antibodies to adhesion molecules in toxic ARF 1125
Fig. 1. In vivo saturation of rat peripheral blood leukocytes (PBLs) by antileukocyte function associated antigen-1 (anti-LFA-1; WT.1) binding.
(A) Flow cytometric analysis of rat PBL labeled with anti–LFA-1 [monoclonal antibody (mAb) WT.1] prior to antibody treatment (day 21)
displays three subsets of cells differentially (monocytes . granulocytes . lymphocytes) expressing the antigen. (B) Following injection with control
antibody (day 0), no PBL could be found with mouse mAb on their membranes that would be recognized by rabbit-anti-mouse (RAM) IgG. (C)
In vitro addition of mAb WT.1 displays three subsets of cells differentially expressing the antigen (as in A). (D) Twenty-four hours following
combined in vivo treatment with anti–ICAM-1/anti–LFA-1 (day 0), three subsets of cells differentially (consistent with pattern shown in A) binding
a mouse antibody are recognized by RAM-IgG. (E) In contrast, hardly any in vitro added mAb WT.1 bound to the cells. White overlays
represent nonlabeled autofluorescent controls. Abbreviations are: RAM-IgG, biotinylated rabbit-anti-mouse immunoglobulins; SA-PE, streptavidin-
phycoerythrin conjugate.
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as 600/mm2 after induction of ARF (Fig. 3 B, C). Also,
CD8-positive cells (cytotoxic/suppressor T cells and nat-
ural killer cells) were significantly increased in these rats
(Fig. 3 E, F), as were CD4-positive cells (helper cells
and macrophages; Fig. 3 H, I). By contrast, the combined
treatment with anti–LFA-1/anti–ICAM-1 mAbs up to
day 4 maintained renal numbers of macrophages (Figs.
3A and 4) as well as cytotoxic/suppressor T lymphocytes
(Fig. 3D) and helper T cells (Fig. 3G) comparable or
less to those in control conditions (prior to injury). The
interstitial presence of polymorphonuclear cells was not
increased in any of the treatment groups as compared
with noninjured control rats (data not shown).
Acute renal failure
Body weight and renal function. Transient functional
deterioration was equally pronounced in all HgCl2-treated
groups, being maximal at day 2 [Fig. 5 A–C: serum creati-
nine (mg/dL) anti-ICAM-1/anti-LFA-1 treated, 2.11 6
1.78; control antibody treated, 1.60 6 1.21; vehicle
treated, 1.71 6 1.26; Fig. 6 D–F: urinary protein excretion
(mg/24 hours) anti–ICAM-1/anti–LFA-1 treated, 18.36 6
14.64; control antibody treated, 18.38 6 11.46; vehicle
treated, 21.68 6 11.73] and returning to preinjury values
at day 8 (serum creatinine) and day 6 (urinary protein
excretion). Nevertheless, the protective effect of anti–
ICAM-1/anti–LFA-1 antibody treatment as applied in
these HgCl2 ARF rats was proven by comparison of
serum creatinine values of control mAb-treated ischemic
rats with serum creatinine values of anti–ICAM-1/anti–
LFA-1 treated ischemic rats. The former rose signifi-
cantly higher (3.80 6 0.20 mg/dL) 24 hours after exposure
to ischemia than the latter (2.20 6 0.95 mg/dL). Variation
in individual body weight (initial weight loss until day 3,
stabilization and weight gain thereupon) did not differ
between the different HgCl2 treatment groups (data not
shown; paired t-test of data from days 21,1, 2, 4, 6, 8,
and 10 with day 0.)
Renal tubular morphology. After the injection of mer-
curic chloride, proximal tubular epithelial cell injury be-
came equally pronounced in all treatment groups, with
up to 50% of the examined S3 segment cross-sections
appearing completely necrotic at day 2 (Fig. 6). Only
minor lesions were seen in proximal convoluted tubules
and in distal tubules (data not shown). Necrotic tubularFig. 2. In vivo binding to rat endothelium of injected anti-intercellular
adhesion molecule-1 (ICAM-1; mAb WT.1). Immunohistochemical cells were gradually replaced by healthy cells at a compa-
staining by mere addition of secondary polyclonal (horse-anti-mouse) rable rate in all treatment groups.
antibody, that is without primary specific mAb of (A) renal tissue
Tubular epithelial cell and interstitial cell prolifera-sections originating from rats treated with anti–ICAM-1/anti–LFA-1
mAbs revealed intense staining in the renal interstitium as well as tion. Twenty-four hours after mercuric chloride injec-
in glomeruli presumably representing ICAM-1–expressing endothelial tion, PCNA-positive cells were almost completely absent
cells to which injected mouse-anti-rat ICAM-1 (mAb 1A29) is bound.
in proximal straight (S3) tubules (Fig. 7 A–C). By day 2,(B) Renal tissue originating from rats treated with control mAb were
negative. (C) Immunohistochemical staining with anti–ICAM-1 mAb their number had significantly increased, and this was
from renal tissue obtained from rats treated with control mAb four equally pronounced in all treatment groups. Thereafter,
days after mercuric chloride injection shows the ICAM-1 expression to
individuals of both control antibody and vehicle-treatedcorrespond with horse-anti-mouse staining pattern in A (magnification
10 3 1.25 3 25). groups continued increasing their number of PCNA-posi-
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Fig. 3. Interstitial infiltration of mononuclear cells. The number of positive cells upon immunohistochemical staining of renal tissue sections with
(A–C ) mAb ED1 (macrophages), (D–F ) mAb OX-8 (CD8-positive cells), and (G–I ) mAb OX-35 (CD4-positive cells). Whereas control antibody
(B, E, and H) and vehicle (C, F, and I)-treated rats showed marked interstitial numbers of these three leukocyte subsets, infiltration was suppressed
in anti–ICAM-1/anti–LFA-1 (A, D, and G) treated rats. Nevertheless, macrophages were apparent at day 6 in the anti-adhesion treated group.
*P , 0.05 as compared with non–HgCl2-injected control within one treatment group. #P , 0.05 between anti-adhesion and control mAb-treated
groups. 8P , 0.05 between anti-adhesion and vehicle-treated groups.
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Fig. 4. Macrophages in the rat kidney after
HgCl2 injection. Immunohistochemical stain-
ing of renal tissue sections obtained at day 4
from (A) control antibody-treated rats and
(B) anti–ICAM-1/anti–LFA-1 treated rats.
Microwave treatment 1 mAb ED1 (magnifi-
cation 10 3 1.25 3 25).
tive S3 segment cells to a maximum at day 4. By day 10, flammatory leukocytes to a site of injury. The initiation
proximal tubular cell proliferation had returned closely of these events is mostly due to tissue damage, which
back to normal in each group. Also, distal tubular cells can trigger the release of early inflammatory cytokines
showed generally increased PCNA positivity, which in such as IL-1 and TNF-a, and thereby induce the expres-
both control antibody and vehicle-treated groups started sion of a number of chemokines as well as the up-regula-
and peaked already at day 2, while the anti–ICAM-1/ tion of adhesion molecules. Injection of 2 mg/kg mercuric
anti–LFA-1 treated group showed pronounced distal tu- chloride in the rat results in rapid renal tubular epithelial
bular cell proliferation only at day 6 (Fig. 7 D–F). Some cell necrosis, which is maximal already after 24 hours
interstitial cells were PCNA positive in all three groups [49, 50] and which mainly affects the proximal straight
(Mann–Whitney U-test, *P , 0.05 as compared with tubule (PST). Backleak of tubular fluid caused by ob-
non-HgCl2 injected control within one treatment group; struction and tubuloglomerular feedback, both causing
Fig. 7 G–I). an increase of serum creatinine concentration (used as
measure of renal function), are secondary to the necrotic
DISCUSSION lesions [51]. In the present experiment, injection of rats
with HgCl2 characteristically induced severe renal tubu-Local expression of chemoattractant cytokines are
thought to be responsible for the accumulation of in- lar epithelial cell necrosis in the PST, and this was equally
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Fig. 5. Alterations in renal function. (A–C ) Serum creatinine concentration and (D–F ) urinary protein excretion increased after mercuric chloride
injection to a maximum at day 2, after which both these parameters for renal function recovered. The alterations were equivalent in all treatment
groups. (Paired t-test between data from days 21, 1, 2, 4, 6, 8, and 10, and day 0.)
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Fig. 6. Proximal tubular epithelial cell injury in the outer stripe of the outer medulla. Within 24 hours after mercuric chloride injection, pronounced
proximal (S3 segment) tubular necrosis had evolved, which increased somewhat by day 2. Thereafter, necrotic cells were gradually replaced by
healthy cells, and this at a comparable rate in all groups.
pronounced in the anti-adhesion versus control treat- of the rat kidney by in vivo treatment with antibodies
to ICAM-1 in a toxic ARF model utilizing cisplatin [33].ment groups. Nevertheless, kidneys from rats treated with
anti–LFA-1/anti–ICAM-1 mAbs resulting in sustained Why is there no protection of kidneys to HgCl2-induced
toxic injury as opposed to ischemia/reperfusion injurymeasurable serum concentrations of these antibodies were
devoid of interstitial leukocytes during the early phase or even cisplatin-induced toxic injury when rats are
treated in vivo with antibodies to adhesion molecules?of the disease (up to and including day 4). This preven-
tion of infiltration/proliferation did not affect the renal Indeed, the course of ARF seems quite similar in both
models and is characterized by rapid nephron subseg-functional decline at all, which was equally pronounced
in all groups (maximum at day 2) and which showed ment-specific ATN, a transient rise of serum creatinine
concentration and temporary proteinuria [8, 52]. A well-identical recoveries when measured as serum creatinine
concentration and as urinary protein excretion. Similarly, coordinated regeneration process reverses these disease
parameters within one or two weeks following the insult,necrotic tubular cells were gradually replaced by healthy
cells at comparable rates in all treatment groups. Thus, and in either model, sustained lesions are only occasion-
ally present. A renal interstitial leukocyte infiltrate quali-prolonged treatment with antibodies to ICAM-1 and
LFA-1 clearly resulted in the prevention of leukocyte tatively and quantitatively similar in both toxic and ische-
mic acute renal injury generally starts emerging 24 hoursinfiltration/proliferation but did not influence mercuric
chloride (toxic) ARF functionally or morphologically. following the initial insult and becomes prominent at 48
hours. These macrophages and T lymphocytes preferen-Notwithstanding, similar anti-adhesion treatment was ef-
fective in preventing renal functional decline following tially reside in the most severely injured renal zone and
again leave/disappear from the kidney after the regener-ischemic injury of the kidney.
The protective potential of anti–ICAM-1 treatment in ation process is complete [11]. Notwithstanding such
striking resemblance in disease progression, the initialischemic ARF (but not in HgCl2 ARF) had been demon-
strated earlier by Kelly et al, who by a single injection early events in toxic and ischemic ARF are essentially
different. Experimental ischemic/reperfusion injury is in-of anti–ICAM-1 mAbs could prevent the decline in renal
function (as measured by the rise of serum creatinine duced mainly by clamping renal artery and vein [53, 54].
Subsequent reduction of the single nephron glomerularconcentration) following 30 minutes of bilateral renal
ischemia and subsequent reperfusion in the rat [27]. filtration rate (SNGFR) and consequent decrease of the
“whole kidney” glomerular filtration rate (GFR) haveExperiments by the same investigators with ICAM-1
knockout mice had led to equivalent findings [31], and been shown to be the primary cause of serum creatinine
increase in these cases [55], while in addition, increasedsimilar conclusions were also drawn from experiments
with antisense oligonucleotides to ICAM-1 [32]. In addi- renal vascular resistance and reduced renal blood flow
(RBF) appeared to be maintained for up to 48 hourstion, Kelly et al recently reported functional protection
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Fig. 7. Proliferating cell nuclear antigen (PCNA) expression as an indicator of cell proliferation. PCNA positivity was highest in proximal tubules
(A–C ), although some distal tubular (D–F ) as well as interstitial (G–I ) cell proliferation also was apparent. Peak proliferation in proximal tubules
(day 4) was higher in control antibody (B) and vehicle (C)-treated rats as compared with anti–ICAM-1/anti–LFA-1 (A)-treated rats. Also, distal
tubular proliferation started sooner (day 2) in control antibody (E) and vehicle (F) treated rats as compared with anti-adhesion treated rats (D).
*P , 0.05 as compared with non-HgCl2 injected control within one treatment group.
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after ischemia. Toxic ARF is experimentally induced when an increase of MPO activity and serum creatinine
are already reversing and when morphological injury noby an injection of a compound that becomes directly
tubulotoxic [49]. Conger and Falk demonstrated that the longer augments [8, 11]. Clearly, there seems to be a
single nephron glomerular filtration rate (SNGFR) after dissociation between the time sequence of leukocyte in-
HgCl2 injection was unchanged when measured at Bow- filtration and increase of MPO activity. One could sug-
man’s space, but when measured in the late proximal gest that MPO activity serves more adequately as a
tubule, SNGFR was significantly reduced [51]. More- marker for leukocyte activation rather than as a measure
over, a reduction of the glomerular ultrafiltration coeffi- for leukocyte number. Therefore, one could argue that
cient in this case was not associated with alterations in PMN cells and/or other leukocytes act during ischemia
glomerular plasma flow and glomerular capillary pres- by means of a “hit and run” phenomenon, during which
sure. The authors concluded that backleak of tubular they do not infiltrate, but only attach to the endothelium
fluid secondary to the necrotic lesions is the primary long enough either to release highly reactive enzymes
cause of decreased GFR and rise of serum creatinine in and oxygen species, or to support molecular interactions
HgCl2 ARF, while alterations in renal hemodynamics involving ICAM-1 presumably inducing intracellular sig-
seemed less important in this model. For a matter of naling events controlling vascular tonus or to simply
completeness, it should be mentioned that when mercu- block vascular flow in the capillary network [65, 66]. That
ric chloride was administered to rats at extremely high ICAM-1 must be an important target at an early stage in
doses (5 to 12 mg/kg), some authors no longer could the disease process of renal ischemic/reperfusion injury is
exclude a vascular component as contributing to the re- indeed indicated by the fact that anti–ICAM-1 mAbs
duction of whole kidney GFR [56–58]. Finally, direct were effective in Kelly et al’s experiment when given
toxicity to renal tubular epithelial cells associated with before, during, or two hours after ischemia; however,
vascular congestion is said to contribute to renal dysfunc- when given eight hours after ischemia, the antibody ef-
tion following exposure to cisplatin [59–61]. fect was abrogated. That such initial renal vascular alter-
Kelly et al interpreted the results obtained by ischemic ations cannot be demonstrated in mercuric chloride ARF
models as supportive for the widely accepted concept but are important in cisplatin-induced renal pathology
that PMNs, which are thought to be the major source [59–61] may explain why antibodies to ICAM-1 also pre-
of myeloperoxidase (MPO), are important mediators of vent increased serum creatinine in the latter model, but
ischemic/reperfusion injury. Indeed, they found that remain ineffective in HgCl2 ARF.
MPO activity in renal tissue homogenates from anti– In conclusion, treatment with anti–LFA-1/anti–ICAM-1
ICAM-1-treated rats was reduced as compared with this mAbs clearly prevented leukocyte influx/proliferation in
from control mAb-treated rats, the latter of which was the HgCl2-injured kidney when compared with control
markedly increased as early as 4 hours after release of antibody treatments. Transient functional deterioration
clamps, rising until 24 hours, but decreasing thereafter. and regeneration were nevertheless equally pronounced
Anti–ICAM-1 mAbs were thus considered to have inhib- in all HgCl2 ARF groups, whereas anti–ICAM-1/anti–
ited PMNs from adhering/infiltrating the ischemic kidney LFA-1 treatment resulted in functional protection of rat
and from releasing their highly reactive substances (pro- kidneys from ischemia. Hence, treatment with mAbs di-
teolytic enzymes, oxygen radicals, etc.), which would oth- rected against ICAM-1 and LFA-1 does not lessen or ag-
erwise have caused significant damage and an associated gravate mercuric chloride-induced ARF in the rat. The
rise in serum creatinine. It has been insufficiently investi- absence of an anti–ICAM-1/anti–LFA-1 antibody treat-
gated, however, which cells are actually responsible for ment effect in HgCl2 as opposed to ischemic ARF or to
this early increased renal MPO activity. Bradley et al toxic (cisplatin) ARF associated with hemodynamic alter-
emphasized that MPO measurement indicates neutro- ations reflects the relative unimportance of the vascular
phils as well as macrophages, since both leukocyte sub- component leading to reduced GFR in the HgCl2 ARF.
sets contain the enzyme [62]. Other methods frequently
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